Status:

COMPLETED

Tenofovir in Late Pregnancy to Prevent Vertical Transmission of Hepatitis B Virus

Lead Sponsor:

New Discovery LLC

Collaborating Sponsors:

Gilead Sciences

Conditions:

Hepatitis B Infection

Chronic Infection

Eligibility:

FEMALE

20-35 years

Phase:

PHASE4

Brief Summary

Immunoprophylaxis failure of hepatitis B virus (HBV) leading to vertical transmission remains a concern and has been reported in approximately 8-15% of infants born to hepatitis B e antigen (HBeAg) po...

Detailed Description

Eligible mothers will be randomized (1:1) to either TDF-treated group or untreated group with about 100 subjects in each arm. The treatment group will receive TDF starting at week 30-32 of gestation u...

Eligibility Criteria

Inclusion

  • documented CHB infection with HBsAg positive \> 6 months
  • HBeAg+ CHB pregnant women
  • gestational age between 30-32 weeks
  • HBV DNA \> 6 log10 copies/mL (or \>200,000 IU/mL)
  • both mother and father of the child are willing to consent for the study
  • Major

Exclusion

  • co-infection with hepatitis A, C, D, E, HIV-1 or sexually transmitted disease (STD)
  • decompensated liver disease or significant co-morbidity
  • history of abortion, or diagnosis of fetal defect, or congenital malformation in prior pregnancy
  • antiviral used within six months prior to this pregnancy, or history of renal or tubular function impairment due to adefovir.
  • requirement for other medication during pregnancy to manage other chronic disease(s) or concurrent treatment with immune-modulators, cytotoxic drugs, or steroids
  • the biological father of the child had CHB
  • clinical signs of threatened miscarriage in early pregnancy
  • evidence of hepatocellular carcinoma
  • maternal alanine aminotransferase (ALT) \> or = 5 x upper limit of normal (U/mL), or Total Bilirubin \> or = 2, or glomerular filtration rate (GFR) \< 100, or Albumin \< 25 g/L
  • evidence of fetal deformity by ultrasound examination
  • patient is participating other clinical study

Key Trial Info

Start Date :

March 1 2012

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 28 2018

Estimated Enrollment :

200 Patients enrolled

Trial Details

Trial ID

NCT01488526

Start Date

March 1 2012

End Date

June 28 2018

Last Update

December 9 2019

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

Southwest Hospital

Chongqing, Chongqing Municipality, China, 400038

2

The Fifth Hospital of Shijiazhuang

Shijiazhuang, Hebei, China, 050021

3

Nanyang Central Hospital

Nanyang, Henan, China, 473000

4

The Second Affiliated Hospital of the Southeast University

Nanjing, Jiangsu, China, 210003